13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005548-17-FR
(EUCTR)
28/04/201503/06/2015TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR:A CONTROLED OPEN-LABEL STUDYTREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR:A CONTROLED OPEN-LABEL STUDY PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR
MedDRA version: 18.0;Level: PT;Classification code 10029864;Term: Nystagmus;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: NEURONTIN
Product Name: Gabapentine
Product Code: N03AX12
Other descriptive name: GABAPENTIN
Trade Name: EBIXA
Product Name: MEMANTINE
Product Code: N06DX01
INN or Proposed INN: MEMANTINE
HOSPICES CIVILS DE LYONNULLNot RecruitingFemale: yes
Male: yes
Phase 2France
2NCT01744444
(ClinicalTrials.gov)
November 201230/11/2012Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple SclerosisPendular Nystagmus Patients With Multiple SclerosisDrug: Memantine;Drug: GabapentinHospices Civils de LyonNULLCompleted18 YearsN/ABoth10Phase 2France
3EUCTR2008-000490-37-IT
(EUCTR)
26/02/200820/03/2008Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - NDPharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10028053;Term: MS
Trade Name: EBIXA
INN or Proposed INN: Memantine
OSPEDALE S. RAFFAELENULLNot RecruitingFemale: yes
Male: yes
40Phase 2Italy
4NCT00638833
(ClinicalTrials.gov)
September 200712/3/2008Memantine Therapy for Multiple SclerosisPilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple SclerosisMultiple SclerosisDrug: Memantine;Drug: PlaceboClinica Universidad de Navarra, Universidad de NavarraH. Lundbeck A/STerminated18 Years65 YearsBoth20Phase 2Spain
5EUCTR2007-000503-15-IT
(EUCTR)
19/02/200720/04/2007Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple SclerosisExperimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta.
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: EBIXA
INN or Proposed INN: Memantine
AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
6NCT00638027
(ClinicalTrials.gov)
July 200610/3/2008Memantine for Spasticity in MS PatientsMemantine for Spasticity in MS PatientsMultiple SclerosisDrug: placebo;Drug: memantineUniversity of RochesterForest LaboratoriesCompleted18 Years70 YearsAll21Phase 4United States
7NCT01074619
(ClinicalTrials.gov)
September 200512/9/2005Study on Cognitive Disorders of Multiple SclerosisEffects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple SclerosisMultiple SclerosisDrug: Memantine;Drug: PlaceboUniversity Hospital, CaenMinistry of Health, France;H. Lundbeck A/SCompleted18 Years60 YearsBoth90Phase 3France
8NCT00300716
(ClinicalTrials.gov)
April 20048/3/2006Trial of Memantine for Cognitive Impairment in Multiple SclerosisDouble Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple SclerosisMultiple Sclerosis;Cognition DisordersDrug: MemantineOregon Health and Science UniversityForest Laboratories;University of Southern California;University of Texas Southwestern Medical Center;MS-Hub SeattleCompleted18 Years65 YearsAll82Phase 2/Phase 3United States